Prostate Cancer Detection Clinical Trial
Official title:
Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the
prostate cancer, its specivity is not sufficient. Several PSA variations were defined in
order to increase the specivity of the test, but they aren't much more effective than the PSA
alone for detection of disease.
In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat
cancer disease.
In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA),
zinc/PSA, levels for early detection of the prostate cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04291742 -
Comparison of Prostate Fusion Biopsies With Software and Cognitive
|
N/A |